SETD2 deficiency in chronic myeloid leukemia (CML) contributes to tyrosine kinase inhibitor (TKI) resistance and disease acceleration by enhancing genetic instability and rewiring cellular metabolism and might be a novel biomarker of high risk disease since diagnosis
Observational analysis shows SETD2 loss enhances genetic instability in chronic myeloid leukemia, suggesting it may serve as a biomarker for high-risk disease.
Key Points
SETD2 loss contributes to TKI resistance and genetic instability in chronic myeloid leukemia.
SETD2-deficient cells demonstrated an over 50% increase in leukemic cell propagation through loss-of-function mutations.
This study integrated advanced sequencing techniques like RNA-seq and ChIP-seq to analyze gene expression changes in CML models.
SETD2 deficiency may act as a biomarker of high-risk disease at diagnosis, highlighting the need for further investigations.